Prognostic impact of hypoxia imaging with 18f-fluoroerythronitroimidazole with integrated positron emission tomography and computed tomography in non-small cell lung cancer.

Abstract

e21088 Background: Tumor hypoxia is considered to be an independent predictor of poor prognosis, as well as associated with an increased likelihood of local recurrence and distant metastasis. The study investigated the prognostic effect of pretherapy 18F-Fluoroerythronitroimidazole (18F-FETNIM) integrated positron emission tomography and computed tomography (PET/CT) on survival and analyzed whether 18F-FETNIM uptake of tumor tissue could predict tumor recurrence and distant metastasis in non-small cell lung cancer (NSCLC). Methods: Twenty patients with pathologically confirmed NSCLC who had not undergone treatment were enrolled in the study. Tumour tissue oxygenation was measured with 18F-FETNIM PET/CT. Patients received 357 MBq (range, 274 to -369 MBq) of 18F-FETNIM intravenously and then rested for approximately 120 minutes before undergoing PET/CT. The maximum standard uptake value (SUVmax) of tumor tissue was calculated. There were 24 months in the follow-up period. PET data were correlated with clinical follow-up data. Results: Patients with a SUVmax greater or equal to the median (1.7) had significantly worse survival than those with a SUVmax less than 1.7 (p = 0.048). The SUVmax was found to have a statistically significant correlation with the risk of tumor recurrence or (and) distant metastasis (p = 0.028). Conclusions: Our preliminary results indicate that 18F-FETNIM uptake of tumor tissue shows a strong trend to be a prognostic measure, and SUVmax could predict tumor recurrence or distant metastasis in NSCLC. No significant financial relationships to disclose.